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Cellular heterogeneity represents one of the greatest challenges in cancer therapeutics. In many malig-
nancies, this heterogeneity is generated during tumor evolution through a combination of genetic alterations
and epigenetic events that recapitulate normal developmental processes including stem cell self-renewal
and differentiation. Many, if not most, tumors display similar hierarchal organization, at the apex of which
are ‘‘stem-like cells’’ that drive tumor growth, mediate metastasis, and contribute to treatment resistance.
Using breast cancer as a model, we discuss how an improved understanding of tumor cellular heterogeneity
and plasticity may lead to development of more effective therapeutic strategies.Introduction
Generation of Cellular Heterogeneity during
Carcinogenesis and Tumor Evolution
Several models have been proposed to explain cellular hetero-
geneity within tumors. The clonal evolution model has focused
on random mutation and clonal selection to generate cellular
heterogeneity. Elegant mutational analysis has demonstrated
the existence of numerous sub-clones within solid tumors
including breast cancer (Kandoth et al., 2013). Cells within these
sub-clones may interact through paracrine interactions (Zhang
et al., 2015; Rajaram et al., 2015; Fillmore et al., 2010). Further-
more, several studies have demonstrated both genetically
similar and genetically diverse sub-clones in primary tumors
and metastases in individual patients (Ding et al., 2010; Vignot
et al., 2013), consistent with clonal evolution models. The cancer
stem cell (CSC) model posits that tumors are hierarchically orga-
nized and, at the apex of the hierarchy, are cells that display stem
cell properties. These properties include self-renewal, as well as
the ability to generate more differentiated cells forming the bulk
of the tumor. Hierarchical tumor organization was first demon-
strated in human leukemia (Bonnet and Dick, 1997). This was
followed by the demonstration that solid tumors, including those
of the breast (Al-Hajj et al., 2003), colon (O’Brien et al., 2007;
Ricci-Vitiani et al., 2007), brain (Singh et al., 2004), ovaries
(Zhang et al., 2008), lungs (Eramo et al., 2008), prostate (Collins
et al., 2005), and pancreas (Li et al., 2007) display a similar hier-
archical organization The existence of CSCs in melanoma re-
mains controversial, since the ability of human melanoma cells
to initiate tumors in immunosuppressed mice was shown to be
dependent on the mouse model system utilized (Quintana
et al., 2008). Nevertheless, the preponderance of evidence sug-
gests that the vast majority of both hematologic and solid tumors
contain cells that display stem cell properties (Visvader and Lin-
deman, 2008). In these tumors, cells displaying protein markers
including CD44, CD133, or the enzyme aldehyde dehydroge-
nase (ALDH) were able to generate tumors when transplanted
into immunocompromised mice (Bonnet and Dick, 1997; Al-
Hajj et al., 2003; Ginestier et al., 2007). These transplanted cells
generated tumors that recapitulated the phenotypic heterogene-260 Cell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc.ity of the initial tumor. Although CSCmarkers have proven useful
for the enrichment of CSC populations, their utility is limited by
variability of expression and regulation by environmental factors.
As a result, definitive identification of CSCs requires functional
assays demonstrating the capacity to initiate tumors in mouse
models.
As has been emphasized by others, stochastic clonal evolu-
tion and stem cell models are not mutually exclusive. CSCs
may serve as the unit of selection in the genetic evolution of
tumors while also being genetically unstable, generating multiple
clones consisting of genetically altered CSCs and their differ-
entiated progeny (Figure 1). Furthermore, as discussed below,
cancer cells display a remarkable degree of phenotypic plas-
ticity, and there is evidence that more differentiated tumor cells
may acquire ‘‘stem cell’’ properties through a ‘‘dedifferentiation’’
process, a phenomenon with significant clinical implications.
Interpretations of mouse transplantation studies are limited
by the environmental perturbations associated with these ap-
proaches. To circumvent these limitations, a number of groups
have employed lineage tracing to demonstrate the generation
and propagation of CSCs. For example, Parada’s group has
demonstrated that a Nestin-driven GFP reporter marks neural
stem cells in the brain subventricular zone as well as a corre-
sponding population of glioma stem cells. These Nestin/GFP+
cells repopulate the tumor after treatment with chemotherapy
or genetic ablation (Chen et al., 2012). Similar lineage tracing
studies utilized stage-specific Cre-recombinase labeling to
demonstrate the presence of stem cells in a squamous carci-
noma model system (Driessens et al., 2012). Elegant lineage
tracing has been reported by the Clevers group who employed
this method to follow the fate of colon stem cells during carci-
nogenesis. Using a confetti reporter, in which Cre randomly
activates one of four fluorescent reporters, it was shown that
intestinal adenomas originate in cells expressing the stem cell
marker Lgr5 (Schepers et al., 2012). These studies and others
have provided support to hierarchal models of tumor develop-
ment in which cells that display stem-like properties drive tumor
initiation and propagation. In this Perspective, we will discuss
the mechanisms that generate cellular heterogeneity during
Figure 1. Cellular Heterogeneity and Plasticity in Breast Cancer
Recent work has identified two distinct types of CSCs in breast cancer: a mesenchymal, quiescent type marked by being CD44+/CD24 (EMT-CSCs) and an
epithelial, proliferative type identified as ALDH+ (MET-CSCs). A double-positive CD44+/CD24/ALDH+ population with even higher tumorigenicity exists, but it is
yet to be determined if this is a stable or transient population. The transition between these states is common in vitro and is likely to be regulated by multiple cell
types in the tumor microenvironment through IL-8, Notch, and GH (growth hormone) signaling as well as paracrine interactions between CSCs and their more
differentiated progeny. Derived from these two CSC states are two differentiated bulk tumor cell types: an epithelial type produced by MET-CSCs (common in
most of the molecular subtypes) and a group of mesenchymal bulk tumor cells derived from EMT-CSCs (rare in the majority of breast cancer cases, but common
in the claudin-lowmolecular subtype). Among the corollaries of this model is the idea that the probability of dedifferentiation is not uniform, but is instead inversely
proportional to the number of cellular divisions removed frombeing aCSC. Furthermore,mutations in CSCs generate newCSCs aswell as clones of differentiated
progeny generating cellular heterogeneity during tumor evolution.
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the mediation of therapeutic resistance has been the subject of
excellent recent reviews (Bedard et al., 2013; Burrell et al.,
2013), we will focus on the role of epigenetically generated het-
erogeneity and cellular plasticity in generating tumors driven by
cells that display stem cell properties. We will also discuss the
therapeutic implications of this epigenetic heterogeneity across
the molecular subtypes of breast cancer.
Breast Cancer Stem Cells: Defining the Cell of Origin,
CSCs, and Their Relationships
The CSC hypothesis is composed of two important, but sepa-
rable, components: the first concerns the cellular origin of can-
cer, and the second addresses the nature of cells that are
responsible for tumor maintenance and progression.Cellular Origin of Breast Cancer
Multiple cells within the breast have been proposed as the ‘‘cell
of origin’’ in the development of human breast cancer. An under-
standing of the relationship between cellular hierarchies in the
normal breast is critical to elucidating the cells of origin that
generate the diverse molecular subtypes of breast cancer. Un-
fortunately, studies aimed at understanding this hierarchy in
normal tissue have been complicated by the choice of markers,
plasticity between cell states, and differences between human
and mouse tissue. Early studies utilizing the protein marker
CD24 suggested that the CD24low population (myoepithelial)
had the greatest repopulation capacity compared to CD24hi
(luminal) or CD24neg (non-epithelial) cells (Sleeman et al.,
2006). Further studies using additional markers, however, re-
vealed that both CD24+/CD29hi (Shackleton et al., 2006) andCell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc. 261
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capacity to reconstitute mammary glands, containing both line-
ages when transplanted into the cleared mammary fat pads of
syngeneic mice. In addition to the controversies surrounding
the selection of stem cell markers, there has been debate con-
cerning the relative importance of bipotent and unipotent luminal
and myoepithelial stem cells during normal development and
carcinogenesis.
Lineage tracing experiments using a series of cytokeratins
driving Cre-Recombinase demonstrated that while cytokeratin
14 (K14) marks a multi-potent progenitor capable of gener-
ating all of the mammary lineages during development, unipo-
tent basal and luminal stem cells are responsible for lineage
maintenance (Van Keymeulen et al., 2011). However, subse-
quent cytokeratin-5-driven lineage-tracing studies reported
that both bipotent mammary stem cells MaSCs and unipotent
luminal and myoepithelial progenitor cells are involved in
morphogenesis and homeostasis (Rios et al., 2014). Two
important recent publications have shed further light on ques-
tions concerning the cellular origin of breast cancers as well as
the relative roles of particular oncogenic drivers versus the cell
of origin in determining their phenotype. Reports by two inde-
pendent groups using mouse mammary models (Koren et al.,
2015; Van Keymeulen et al., 2015) revealed that the introduc-
tion of oncogenic PIK3CAH1047R, a common mutation found
in human breast cancer, into either luminal or basal restricted
mammary progenitor cells resulted in dedifferentiation, en-
dowing the cells with multilineage potential. Furthermore, the
phenotype of the transduced cell determined the phenotype
of the resulting tumors. These studies suggest the combined
importance of particular genetic alterations and the cell of
origin in determining molecular characteristics and clinical
behavior of breast cancers. Although it remains to be deter-
mined if similar mechanisms are involved in the generation
of human breast cancer phenotypes, the marked similarities
in gene expression profiles in these mouse models and human
breast cancers suggest that this may be the case (Van Key-
meulen et al., 2015).
In parallel to studies in murine mammary development, eluci-
dations of stem cells in the human mammary gland have
relied on marker expression coupled with functional assays
including mammosphere formation (Dontu et al., 2003) or trans-
plantation into humanized mouse mammary fat pads (Kuper-
wasser et al., 2004). Quantification of mammary repopulating
units in these mouse models demonstrated that the markers
CD49f+CD29+CD24low identified a cell population capable of
generating human mammary structures composed of luminal
and myoepithelial lineages (Eirew et al., 2008). Additional
studies utilizing the markers CD49f, EpCAM, and CD10 demon-
strated that immature mammary lobules contained the greatest
proportion of stem cells with bi-lineage differentiation potential
(Arendt et al., 2014). This important spatial distribution was
validated by a separate study using a different set of markers
including ALDH1A1, SSEA4, CD44, and CK14+/CK19+ (Honeth
et al., 2015). However, given the significant differences in
anatomy and cellular complexity between human and mouse
mammary glands, the exact relationship between stem cells
in human and rodent models remains to be definitively
determined.262 Cell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc.Guided by the information gathered from the studies on the
mouse and human hierarchies, efforts have focused on those
cells within normal breast tissue that may be the cell of origin
for breast tumors. Although it has been postulated that breast
cancers may arise from normal breast stem cells, it is more likely
that the various molecular subtypes of breast cancer arise from
cells at different levels within the mammary hierarchy. Expres-
sion profiling revealed strong similarities between the claudin-
low subtype and MaSCs, while the basal subtype aligns with
luminal progenitor cells (Shehata et al., 2012). In concordance
with these findings, it was shown that breast tumors in women
with germline BRCA1 mutations contain enriched populations
of luminal progenitor cells. These tumors are most often charac-
terized as the basal molecular subtype (Molyneux et al., 2010).
Pre-clinical studies have suggested that BRCA1 plays an impor-
tant role in mammary stem/progenitor cell differentiation and
that the loss of BRCA1 function in mouse models expands the
population of cells expressing ALDH1, a marker of both normal
and cancer stem-like cells (Molyneux et al., 2010). These and
other studies have led to the suggestion that basal breast can-
cers arise from luminal progenitor cells defined as CD49+/ESA+
(Lim et al., 2009). However, this population itself is heteroge-
neous and includes a sub-population defined by expression of
ALDH, a population recently shown to have properties of epithe-
lial-like multi-potent stem cells (Liu et al., 2014). In addition to
being the cell of origin of basal tumors, ALDH1-expressing
stem/luminal progenitor cells may also be the cell of origin of
other molecular subtypes of breast cancer. Amore differentiated
luminal progenitor may give rise to the most highly differentiated
luminal tumors.
The studies designed to elucidate the cell of origin of the
different molecular subtypes of breast cancer have largely relied
on transduction of activated oncogenes into mammary cells
whose differentiation state is defined by marker expression fol-
lowed by transplantation into the mammary fat pads of immuno-
suppressed mice. These studies have suggested that both the
cell of origin and the specific oncogenic events contribute to
the diversity of molecular subtypes of breast cancer. However,
these studies are limited by potential artifacts introduced by
transplantation. As previously noted, Rios et al. (2014) have
demonstrated that normal mouse mammary stem cells maintain
the capacity for multiple lineages upon transplantation but
also maintain unipotent lineage differentiation in their normal
unperturbed microenvironment as accessed by lineage tracing.
Application of similar lineage tracing technologies to mammary
carcinogenesis may provide a more definitive characterization
for the cell of origin of murine mammary cancers. Extrapolation
to human disease will necessitate the utilization of transplanta-
tion technologies. The elucidation of the cell of origin of human
breast cancers is of considerable importance in developing
effective cancer prevention strategies.
CSC State Plasticity and the Tumor Microenvironment
Recent work has demonstrated that breast cancer stem cells
(BCSCs) maintain the plasticity to transition between two
different phenotypic states: a more proliferative epithelial-like
state characterized by expression of the CSC marker ALDH
and a more quiescent and invasive, mesenchymal-like state
characterized by the expression CD44+/CD24. These states
share the molecular characteristics of both luminal and basal
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CSC states is also capable of generating their respective epithe-
lial or mesenchymal bulk cell progeny, which can secrete signals
to positively reinforce CSC self-renewal (Zhang et al., 2015; Fill-
more et al., 2010). Transition between the two CSC states is
mediated by epigenetic alterations regulated by the tumor
microenvironment through cytokine and chemokine signaling,
transcriptional regulation (including differential expression of
microRNAs; Pal et al., 2015), or some combination thereof
(Figure 1). These concepts expand upon previous work that sug-
gested an important relationship betweenCSCs and the process
of epithelial mesenchymal transition (EMT) (Mani et al., 2008). In
the expanded model, EMT-like CSCs are localized at the tumor
invasive edge where they are capable of entering the circulation
and forming micro metastases at distant sites. The transition
back to the proliferative epithelial state at distant sites is medi-
ated by factors such as ID1, which, through downregulation of
TWIST, induce this phenotypic switch (Stankic et al., 2013).
A thorough understanding of CSCs requires delineation of how
the associated tumor microenvironment mediates the balance
between the two CSC states. Unfortunately, while recent
experiments using syngeneic mousemodels and transplantation
into immunocompetent hosts have confirmed the existence of
CSCs in the presence of immune cells, most CSC experiments
have so far been done in immunocompromised mouse models.
These and other studies suggest that CSCs may deploy specific
mechanisms to thwart immune surveillance (Pan et al., 2015).
Immune cells are critical components of the tumor microenvi-
ronment, and rapidly accumulating evidence suggests that the
immune system plays a role in carcinogenesis and tumor devel-
opment. This emphasizes the importance of utilizing immuno-
competent models to more fully explore the mechanisms by
which the tumor microenvironment regulates CSCs.
An important issue in CSC biology is whether bulk tumor
cells are capable of ‘‘dedifferentiating’’ into CSCs. If this were
a common occurrence, then the concept of ‘‘CSC states’’ rather
than fixed populations would be applicable. However, in normal
cells, the process of differentiation is very tightly controlled by
epigenetic events involving histone and DNA modifications. As
a result, the differentiation process is largely unidirectional
(Cantone and Fisher, 2013). However, the ability to reprogram
fully differentiated cells into pluripotent stem cells through the
addition of the four Yamanaka factors (Oct3/4, Sox2, Klf4, and
c-Myc) clearly indicates that dedifferentiation can be driven to
occur in normal cells. It is important to note that, in in vitro
systems, this process is extremely inefficient. Furthermore, the
frequency with which such dedifferentiation events occur during
carcinogenesis is a matter of conjecture. Guo et al. demon-
strated that differentiated breast cancer cells could be converted
back to stem-like cells though combined expression of the tran-
scription factors SLUG and SOX9 (Guo et al., 2012). Dedifferen-
tiation has also been shown in gliomas with loss of NF1 and p53
in astrocytes and neurons (Friedmann-Morvinski et al., 2012).
In intestinal tumorigenesis, overexpression of NFkB and b-cate-
nin causes mitotic intestinal epithelial cells to regain stem cell
properties (Schwitalla et al., 2013). However, many of these
studies suggesting dedifferentiation have been performed
in vitro (Guo et al., 2012), and the actual contribution of dediffer-
entiation during carcinogenesis remains unknown. Lineagetracing studies involving stem cells as well as differentiation-
stage-specific promoters in mouse models will be required to
definitively demonstrate the importance of dedifferentiation in
the generation of CSCs. Once a thorough understanding of
how dedifferentiation contributes to cancer initiation and pro-
gression has been achieved, subsequent studies can begin
to analyze how this information can be used to facilitate better
therapeutic treatments. Mathematical modeling has shown
that dedifferentiation and plasticity will substantially reduce the
effectiveness of CSC-directed therapies and increase rates of
resistance across a range of dedifferentiation rates (Leder
et al., 2010).
An extreme version of cancer cellular plasticity is represented
by the phenomenon of ‘‘vascular mimicry,’’ where there is evi-
dence that CSCs from a number of tumor types undergo trans-
differentiation to form vascular-like networks (Maniotis et al.,
1999; Soda et al., 2011; Ricci-Vitiani et al., 2010). In breast
cancer, recent studies have implicated two secretory proteins,
SERPINE2 and SLPI, which are involved in this phenomenon
(Wagenblast et al., 2015). These vascular mimicry networks
have been associated with increased levels of metastasis. How-
ever, a more impactful role could be the generation of an
expanded niche for CSCs, as endothelial cells have been shown
to be important for both normal and CSC regulation.
CSCs and the Molecular Subtypes of Breast Cancer
Data generated over the past several decades suggest that,
rather than being a single disease, breast cancers represent
multiple diseases that can be subdivided into clinical subtypes
based on cellular expression of estrogen and progesterone
receptor (ER and PR, respectively), as well as the growth factor
receptor HER2 (Erb-B2). By this classification, tumors are
classified as hormone-receptor positive (those that express ER
and/or PR), HER2-positive, or triple-negative (TN; those that do
not express ER, PR, or HER2). Gene expression profiling has
expanded upon this classification, defining tumors as luminal-
like (further divided into luminal A and luminal B); HER2-positive,
characterized by amplification of the HER2 gene; or basal-like
(Perou et al., 2000; Sørlie et al., 2001). The development of
specific therapeutic strategies for each of the major pathologic
subtypes of breast cancer has improved outcomes for many
breast cancer patients. In these tailored approaches, ER-posi-
tive breast cancers are treated with hormonal therapies, cancers
with HER2 gene amplification are treated with HER2-targeting
agents and, in the absence of specific targeted therapeutics,
the TN collection of breast cancers is treated with cytotoxic
chemotherapy. These therapeutic approaches have empha-
sized genomic and phenotypic differences between the sub-
types of breast cancer and have been designed to target bulk
tumor cell populations.
In addition to having different cells of origin, the different mo-
lecular subtypes of breast cancer are characterized by different
frequencies of mesenchymal and epithelial CSC types as well as
differentiation states of bulk cell populations. These differences
are illustrated in Figure 2. The clinically aggressive claudin-low
subtype, which is typically a TN breast cancer (TNBC), is charac-
terized by a high proportion of CD44+/CD24low-expressing and
ALDH1-expressing CSCs as well as mesenchymal-like bulk
tumor cells. In contrast the basal subtype, also commonly TN
and often associated with BRCA1 loss of function, containsCell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc. 263
Figure 2. Model Illustrating Variations in
CSCs and Their Differentiated Progeny
across the Spectrum of Breast Cancer
Subtypes
In this model, the different molecular subtypes of
breast cancer are characterized by varying pro-
portions of CSCs in mesenchymal (EMT) versus
epithelial (MET) states as well as differential blocks
in the differentiation hierarchy seen in normal
mammary development.
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bulk tumor cells and a higher proportion of epithelial ALDH1-
positive CSCs. The CSCs give rise to bulk tumor cells that are
characterized by an epithelial morphology and lack of expres-
sion of the steroid hormone receptors ER or PR (Perou, 2011).
The HER2-positive subtype of breast cancer is characterized
by a high proportion of ALDH1-positive CSCs that give rise to
epithelial bulk populations that may or may not express ER
and PR (Korkaya and Wicha, 2013). Luminal B breast cancers
generally express a lower proportion of cells expressing CSC
markers than either HER2-positive or TNBCs. The bulk cells in
these tumors are highly epithelial inmorphology and a proportion
express ER and PR. Luminal A tumors, which have the best
prognosis, display the lowest proportion of cells expressing
CSC markers. These tumors also display the highest proportion
of ER- and PR-expressing cells.
Plasticity between cell types is an important part of normal
biology, both in development and in adult homeostasis to
respond to stimuli and deal with cellular stress; but one hallmark
of cancer is its ability to lower the activation barrier and increase264 Cell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc.cellular plasticity. The processes of EMT
and mesenchymal-epithelial transition
(MET) have been well studied in the
context of cancer biology and have pro-
found implications for the plasticity be-
tween CSC types and their relation to the
molecular subtypes of breast cancer. As
previously mentioned, work from the
Weinberg lab has shown that EMT, driven
by overexpression of mesenchymal tran-
scription factors such as Snail, Twist,
Slug, and/or Sox9 (Mani et al., 2008; Guo
et al., 2012), can induce an EMT pheno-
typic shift, resulting in increased numbers
ofCSCs. Thisplasticity betweencell types
results in significant challenges to therapy
as EMT increases invasion and dissemi-
nationof cellswhile alsodecreasingprolif-
eration and avoiding cytotoxic chemo-
therapy agents (Creighton et al., 2009).
Alternatively, MET allows cells to return
to a highly proliferative state andmediates
tumor relapse at sites of distant metasta-
ses after cessation of treatment (Yao
et al., 2011). The development of drugs
capable of blocking this cellular plasticity,
such as inhibitors of c-Met (Sylvester,
2014) and TGFB (Bhola et al., 2013), bypreventing transition between CSC states may increase the effi-
cacy of CSC-targeting agents. In addition, as described below,
strategies aimed at simultaneous targeting of CSCs and bulk tu-
mor cellsmaybeuseful in overcoming the therapeutic challenges
posed by tumor cell plasticity.
Mutation Profile and CSCs across the Molecular
Spectrum of Breast Cancer
Genetic analysis of breast cancers has demonstrated different
mutational profiles across the subtypes of breast cancer. For
example, the most frequent genetic alteration found in luminal
breast cancers is mutational activation of PI3K signaling
(Creighton et al., 2010). In contrast, TNBCs almost always
contain mutations in p53 and also frequently display deletions
or epigenetic silencing of the PTEN tumor suppressor gene. In
addition to HER2 gene amplification, HER2-positive breast can-
cers frequently display deletions in PTEN, and indeed this is a
likely cause of resistance to HER2-targeted therapies (Dave
et al., 2011; Fabi et al., 2010; Park et al., 2014). BRCA1 germline
mutations or epigenetic silencing of the Brca1 locus are most
frequently associated with TNBCs (Foulkes et al., 2003).
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demonstrated to increase CSC frequency in pre-clinical models
aswell as in patient samples. The different molecular subtypes of
breast cancer are also characterized by distinct profiles ofmicro-
RNA expression, a number of which regulate CSC states (Pal
et al., 2015). In addition to their effects on CSCs, genetic and
epigenetic events produce blocks in normal differentiation path-
ways that differ across the molecular subtypes of breast cancer.
It is notable that despite the diversity of genetic changes driving
the different molecular subtypes of breast cancer, CSCs within
these subtypes have similar patterns of gene expression (Liu
et al., 2014), suggestive of common, shared regulatory path-
ways. For example, the Notch (Al-Hussaini et al., 2011) and
Wnt (King et al., 2012) developmental pathways, as well as
Her2-Akt (Korkaya et al., 2008) and STAT3-NFkB signal (Iliopou-
los et al., 2009) transduction pathways, may play important roles
in the regulation of self-renewal and differentiation of CSCs
across the molecular subtypes of breast cancer. This observa-
tion has important implications for understanding the mecha-
nisms underlying therapeutic resistance and the development
of more effective therapeutic strategies capable of producing
sustained effects.
Therapeutic Implications of CSC Models
Approaches involving more specific targeted therapeutics have
led to improved outcomes, particularly when they are adminis-
tered in the adjuvant setting after surgical removal of the primary
tumor to lessen the probability of tumor recurrence. However,
despite these new options, metastatic breast cancer remains
largely incurable (Ruiterkamp et al., 2011), primarily due to the
emergence of treatment resistance during therapy. Cellular
heterogeneity, generated through genetic and epigenetic mech-
anisms, contributes to the development of treatment resistance.
EZH2, which acts as a transcriptional repressor via control
of the repressive histone modification mark H3K27me3, has
been linked to aggressiveness in breast cancer (Kleer et al.,
2003; Holm et al., 2012). In ER-positive breast cancer, methyl-
ation events have been associated with resistance to both
tamoxifen and aromatase inhibitors (Magnani et al., 2013), and
H3K27me3 marks are correlated with a worse outcome during
aromatase inhibitor therapy (Jansen et al., 2013); pre-clinical
data suggest that treatment of ER-positive breast tumors with
histone deacetylase (HDAC) inhibitors can improve responses
to tamoxifen (Hodges-Gallagher et al., 2007; Thomas et al.,
2011; Bic¸aku et al., 2008). Epigenetic silencingmay also drive tu-
mor cells toward aCSC-like state (Ohmetal., 2007). For example,
in basal breast cancers, activation of Zeb1 via epigenetic modu-
lation of its promoter leads to transition of non-CSCs to CSCs
(Chaffer et al., 2013). Clinically, however, results of trials utilizing
HDAC inhibitors have been mixed. Promising results have been
demonstrated in using these agents to reverse endocrine resis-
tance; however, HDAC inhibitors have not shown single-agent
efficacy in breast cancer (Munster et al., 2011; Luu et al., 2008).
The CSC hypothesis has important clinical implications. CSCs
display relative resistance to cytotoxic chemotherapy, both in
pre-clinical models and neoadjuvant clinical trials (Creighton
et al., 2009). In fact, both chemotherapy and radiation therapy
may actually stimulate CSC self-renewal through cytokine pro-
duction and DNA repair mechanisms (Maugeri-Sacca` et al.,2012; Li et al., 2008; Phillips et al., 2006). The development of
individualized therapies for each molecular subtype of breast
cancer was largely based on strategies to target bulk cell popu-
lations. However, patients inevitably develop resistance to these
therapeutic approaches. The evolution of clones of cells with
‘‘driver’’ mutations undoubtedly contributes to this resistance,
providing a substantial therapeutic challenge (McGranahan
et al., 2015). Genetic mutations, as well as microenvironmentally
driven epigenetic diversity at metastatic sites, further limit the
effectiveness of agents targeting genetic lesions of the primary
tumor (Oskarsson et al., 2014).
Althoughmutations are shared between CSCs and their clonal
progeny (Marusyk et al., 2014), CSCs may be dependent on
alternate pathways, many of which are shared across themolec-
ular subtypes of breast cancer. This suggests that the addition of
CSC targeting agents to molecular-subtype-specific therapies
may improve treatment efficacy. This approach is illustrated in
Figure 3 and discussed in more detail below.
ER-Positive Breast Cancer
Breast cancers that express ER and/or PR have been subdivided
into luminal A and luminal B based on molecular profiling. The
proliferation marker Ki67 has served as a surrogate for molecular
profiling, where a Ki67 index of 14 divides the less proliferative
luminal A breast cancers from the more highly proliferative
luminal B breast cancers (Goldhirsch et al., 2011). Although
both of these luminal breast cancers are treated with hormonal
therapy, the clinical outcome is significantly more favorable for
patients with luminal A tumors compared to luminal B tumors
(Sørlie et al., 2001). It is likely that many luminal A breast cancers
may lack a true CSC and instead consist of a relatively uniform
population of luminal progenitor/differentiated cells that express
steroid hormone receptors; in contrast, luminal B breast cancers
contain a proportion of CSCs that do not express ER or PR (Har-
rison et al., 2013; Horwitz et al., 2008). Of interest, it was recently
reported that despite the fact that ALDH-positive CSCs do not
express the classical 66 kilodalton ERa (ERa66), they may ex-
press ERa36, an alternative ER that is localized in the plasma
membrane and is capable of directly activating mitogenic
signaling (Zhang et al., 2012a; Deng et al., 2014). In luminal
breast cancers, CSCs have been shown to be regulated through
paracrine loops involving estrogen-induced FGF 9 (Fillmore
et al., 2010) and progesterone-induced RANKL (Schramek
et al., 2010). These growth factors, produced by ER/PR-
expressing differentiated cells, regulate the self-renewal of
CSC populations (Fillmore et al., 2010; Rajaram et al., 2015).
In vitro, development of resistance to hormonal therapy is
accompanied by an increase in the CSC population (Piva et al.,
2014; Wang et al., 2012). The clinical relevance of these findings
was evidenced in a study that demonstrated an increase in the
proportion of cells expressing the CSC phenotype CD44+/
CD24 following neoadjuvant hormone therapy (Creighton
et al., 2009). This suggests that simultaneous targeting of CSC
and ERa-expressing differentiated cells might increase the clin-
ical efficacy of hormonal therapy.
In addition to direct mitogenic effects of estrogen, luminal sub-
type CSCs may be regulated by growth factor pathways
including PI3K, mTOR, and HER2 (Ithimakin et al., 2013; Korkaya
et al., 2009; Zhang et al., 2012b; Zhou et al., 2007). It has been
demonstrated that the combination of the mTOR inhibitorCell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc. 265
Figure 3. Strategy for Combining CSC-Targeting Agents with Approved Drugs that Target the Bulk Tumor Populations in Each Molecular
Breast Cancer Subtype
The diagram on the left illustrates CSC-targeting drugs either approved or in development and, on the right, FDA approved drugs to treat each of the molecular
subtypes of breast cancer.
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to tumor progression in ER-positive breast cancer (Baselga
et al., 2012). Similarly in a randomized phase II trial, the addition
of the cyclin-dependent kinase (CDK) 4/6 (CDK4/6) inhibitor pal-
bociclib to endocrine therapy resulted in a near doubling of the
time to tumor progression (Finn et al., 2015). This clinical benefit
has been attributed to the ability of CDK4/6 inhibitors to inhibit
the downstream target of estrogen mitogenic signaling, Cyclin
D. However, it has recently been reported that the CyclinD-
CDK4/6 complex also plays a role in the regulation of self-
renewal in breast CSCs and that palbociclib targets this cell pop-
ulation (Finn et al., 2009; Lamb et al., 2013). This raises the
intriguing possibility that inhibition of CSCs by targeting mTOR
or CDK4/6 may contribute to the clinical benefit of these com-
pounds, supporting the strategy of combining CSC targeting
agents with endocrine therapies that target the ER-positive
bulk tumor populations as illustrated in Figure 3.
HER2-Positive Breast Cancer
The development of HER2-targeted therapeutics for the treat-
ment of HER2-positive breast cancer has been one of the great-
est advances in breast cancer therapeutics. When used in the
adjuvant setting, the HER2-targeting antibody trastuzumab
dramatically reduces breast cancer recurrence (Slamon et al.,
2011). In addition to trastuzumab, other HER2-targeting agents,
including themonoclonal antibody pertuzumab and the immuno-
toxin conjugate ado-trastuzumab emtansine (TDM-1), have
further improved the efficacy of HER2 targeting (Swain et al.,
2013; Verma et al., 2012). The importance of HER2 signaling
in breast cancer pathogenesis and treatment may relate to the
observation that HER2 is an important regulator of BCSC self-
renewal (Giordano et al., 2012; Korkaya et al., 2008). HER2266 Cell Stem Cell 17, September 3, 2015 ª2015 Elsevier Inc.overexpression through gene amplification increases the CSC
population, whereas HER2-blocking agents such as trastuzu-
mab reduce this cell population. Although the use of HER2-
targeting agents has been limited to patients whose tumors
display HER2 gene amplification, retrospective analyses of large
randomized adjuvant trials have suggested that the benefit of
adjuvant trastuzumab may extend to patients with tumors that
did not display HER2 amplification (Paik et al., 2008). The recent
demonstration of HER2 expression in CSCs, in the absence of
HER2 gene amplification, may provide a biological explanation
for these surprising results (Ithimakin et al., 2013). The utility of
HER2 blockade in patients classified as HER2-negative is being
tested in a large randomized clinical trial.
Despite the clinical efficacy of HER2-targeting agents, the vast
majority of patients with metastatic HER2 amplified breast can-
cer eventually develop resistance to these therapies. The most
frequent genetic abnormality associated with this resistance is
deletion of the PTEN gene (Dave et al., 2011). It has been demon-
strated that PTEN deletion in HER2-overexpressing cells acti-
vates cytokine-signaling pathways including IL-6, STAT3, and
NFkB (Korkaya et al., 2012). This pathway generates EMT-like
CSCs. The existence of CSCs inmultiple states, each dependent
on alternative signal transduction pathways,may necessitate the
development of strategies to target these multiple pathways. A
clinical trial adding the IL-6 receptor blocking antibody tocilizu-
mab to HER2-blocking agents is in development (Figure 3).
TNBC
TNBCs are characterized by lack of expression of ER, PR, and
HER2, and these tumors typically have the highest proportion
of cells that express CSC markers compared to the other sub-
types (Idowu et al., 2012). Recent molecular profiling of TNBC
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Perspectivehas further demonstrated the heterogeneity of this group of
tumors. Unlike the other subtypes of breast cancer, there are
currently no targeted therapies that improve patient outcome,
and the only established treatments involve the use of cytotoxic
chemotherapy. Although these therapies are clearly beneficial,
patients invariably develop resistance. This resistance has
been shown to be associated with an increase in CSCs. In
fact, cytotoxic chemotherapy has been demonstrated to actually
increase CSCs through activation of cytokine loops involving
IL-6 and IL-8 (Tsavaris et al., 2002; Samanta et al., 2014). It ap-
pears that a limited repertoire of signal transduction pathways
regulate CSCs of this subtype. Recently, Junankar et al. (2015)
reported that the inhibitor of differentiation-4 (ID4) is a key
regulator of mammary stem cell renewal and marks a subset of
TNBC cases with a particularly poor prognosis. Interestingly,
ID4 expression is unrelated to previous molecular TN classifica-
tions and was found to control mammary stem cell self-renewal
acting upstream of Notch signaling to repress luminal fate
commitment. Other pathways that play important roles in the
regulation of CSCs within this TN subtype include Wnt (King
et al., 2012), Notch (Al-Hussaini et al., 2011), Hedgehog (Liu
et al., 2006), and IL-8-CXCR1 (Rody et al., 2011). Early-stage
clinical trials utilizing inhibitors of these pathways to target
CSCs in women with TNBC are in progress (Figure 3). The
increased efficacy of such combinations may also result from
the induction of cell differentiation in CSCs by the targeted
agents, subsequently rendering the CSCs susceptible to chemo-
therapy. Recently, it has been demonstrated that defects in DNA
repair in TNBC associated with BRCA1 mutation or loss of activ-
ity are susceptible to inhibition of poly-ADP-polymerase (PARP;
Dent et al., 2013; Shen et al., 2013). The sensitivity of BCSC in
these tumors to PARP inhibition remains to be determined.
Another approach to treat TNBC utilizes the targeting of tumor
angiogenesis using VEGF inhibitors such as bevacizumab. Use
of this agent resulted in delayed progression time of patients
with TNBC. However, post-treatment monitoring of this patient
group revealed that, although treatment delayed tumor pro-
gression, once the tumors had progressed they displayed a
more aggressive phenotype, resulting in little, if any, difference
in ultimate patient survival (Wagner Anna et al., 2012). It has
recently been demonstrated that these anti-angiogenic agents
stimulate CSCs through generation of tissue hypoxia, with
resultant stimulation of HIF-1a, a potent regulator of breast
CSCs (Conley et al., 2012). Addition of HIF-1a inhibitors caused
blockage of this effect, causing a decrease in CSCs and
increasing the efficacy of the anti-angiogenic agents in pre-clin-
ical models (Conley et al., 2015).
Most recently, preliminary data suggest that immunotherapy
utilizing an immune checkpoint blocker against PD-L1 benefited
a subset of women with TNBC (L.A. Emens et al., 2015, Am.
Assoc. of Canc. Res. Ann. Meeting, abstract). There is evidence
that CSCs may utilize multiple mechanisms to evade immune
surveillance. Specific strategies for immune targeting of CSCs
are in development.
Implications of CSCs for Clinical Trial Design
The existence of CSCs in the vast majority of breast cancers has
important clinical implications for the development strategies
and design of clinical trials to assess treatment efficacy. As
described above, pre-clinical models provide strong supportfor combining molecular subtype-specific agents with CSC-
targeting drugs. This combined approach also applies to molec-
ular targeted therapies, the selection of which is based on
molecular profiling of bulk tumor cells. It is critical to consider
that, despite their genetic similarities, CSCs and the bulk tumor
cells derived from them may be dependent on different
signaling pathways. These differential sensitivities, presumably
due to epigenetic differences in these cell populations, may
have important implications for the selection of the appropriate
therapeutic regimen and for the selection of appropriate end-
points to access treatment efficacy. The existence of multiple
CSCs in a given tumor presents an additional therapeutic chal-
lenge, which may require the combination of multiple CSC-tar-
geting drugs.
Since CSCs constitute only a minor fraction of tumor cells,
classical clinical endpoints, such as tumor shrinkage as as-
sessed by Response Evaluation Criteria for Solid Tumors
(RECIST), are inadequate to access the efficacy of CSC-target-
ing agents. The assessment of CSC markers in serial tumor bi-
opsies may prove valuable in accessing these effects (Schott
et al., 2013). Alternately, circulating tumor cells (CTCs) have
been shown to be enriched in CSCs (Aktas et al., 2009) and
may provide more readily available liquid biopsies (Pantel and
Alix-Panabie`res, 2013). Neoadjuvant clinical trial designs, in
which primary therapy is given before surgical removal of tu-
mors, afford the opportunity to directly assess the effects of
therapy on both CSC and bulk tumor populations. Indeed,
such studies have demonstrated that persistence of CSCs, as
assessed by expression of ALDH, is associated with increased
development of subsequent metastatic disease (Alamgeer
et al., 2014).
A number of CSC targeting drugs are now being tested in early
stage clinical trials (Figure 3). Following the demonstration of
safety, these drugs are being combined with more traditional
therapies that target bulk cell populations. Ultimately, random-
ized clinical trials will be required to ascertain the benefit of these
combined approaches for treatment of advanced, metastatic
disease. Furthermore, since pre-clinical studies suggest that
the benefit of CSC-targeting agents is greatest when they are
deployed in the adjuvant setting, use of these agents in earlier-
stage disease needs to be tested. The use of rational combi-
nations of agents to target both differentiated tumor cells and
CSCs holds great promise for improved therapeutics in all sub-
types of breast cancer.
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